Bio­Marin seeks la­bel ex­pan­sion for achon­dropla­sia drug; FDA lifts In­hibikase full clin­i­cal hold

Bio­Marin is look­ing to press its ad­van­tage in the achon­dropla­sia, or dwarfism, drug space.

The Cal­i­for­nia com­pa­ny said Tues­day af­ter­noon the FDA will take up its ap­pli­ca­tion to ex­pand the Vox­zo­go la­bel in­to chil­dren younger than 5 years of age. Reg­u­la­tors will make their de­ci­sion by Oct. 21.

Bio­Marin’s move came a day af­ter com­peti­tor Bridge­Bio tout­ed Phase II da­ta for its own achon­dropla­sia pro­gram and sub­se­quent­ly sought a $150 mil­lion stock of­fer­ing. Vox­zo­go was orig­i­nal­ly ap­proved in No­vem­ber 2021 for pa­tients 5 years and old­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.